Precision Plasmid Architecture for Therapeutic Payloads.

Executive Summary

Constructing high-fidelity AAV plasmids, particularly those carrying large or multi-component transgenes, can be a significant manufacturing bottleneck. Traditional cloning methods that rely on restriction enzymes can introduce sequence artifacts and are inefficient for complex assemblies. Franklin Biolabs utilizes advanced Gibson Assembly protocols to build sequence-perfect AAV plasmids, ensuring the precise architecture of the therapeutic payload. This method accelerates plasmid production and provides a superior foundation for developing vectors capable of stable protein expression.

Overcoming the Plasmid Construction Bottleneck

The integrity of an AAV vector’s therapeutic payload is dictated entirely by its plasmid DNA blueprint. Conventional cloning techniques using restriction digestion and ligation are often inefficient for assembling the multiple fragments—promoter, transgene, and polyadenylation signal—that constitute a modern expression cassette. These older methods can leave behind unwanted sequence “scars” that may interfere with transcription or translation.

Gibson Assembly circumvents these limitations. By using a cocktail of enzymes in a single isothermal reaction, the method seamlessly joins DNA fragments with engineered homologous overlaps. This approach provides several distinct advantages for AAV vector development:

• Sequence Integrity: It creates scarless connections between DNA fragments, preserving the precise coding and regulatory sequences.

• Complex Assemblies: It efficiently joins multiple DNA fragments in a single, directional reaction, ideal for cassettes with multiple components.

• Design Flexibility: It eliminates the dependency on available restriction sites, giving scientists complete freedom in designing the transgene cassette.

From Plasmid Architecture to In Vivo Efficacy

A meticulously constructed plasmid is the first step toward achieving desired therapeutic outcomes. The ability to precisely engineer the expression cassette directly influences the potential for achieving sustained protein expression in target tissues. This has been a foundational concept for therapeutic efficacy demonstrated in studies exploring both regulated long-term expression and the use of novel AAV serotypes for specific tissue tropisms.

Our DNA services are built upon decades of experience in vectorology. The Franklin Biolabs brand was launched in 2024, continuing the work of the team that powered the UPenn Gene Therapy Program’s Vector Core. This deep institutional knowledge ensures that every plasmid we produce is optimized for its intended purpose, from codon usage to the selection of regulatory elements. As one biotech partner noted about this transition, “The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption… [providing] continuity for our AAV-vector based gene therapy candidate development.” This continuity of expertise, housed within our >100,000 sq ft facility, underpins the robust plasmid production that serves as the starting point for programs targeting an 18-24 month IND timeline.